NCT04909112

Brief Summary

Sjögren syndrome is an autoimmune disease, responsible for xerostomia and xerophthalmia. Other organs and tissues can be affected: the skin, vaginal and nasal mucous membranes. As well, olfactory disorders have been also described in Sjögren syndrome. Xerostomia often causes significant functional impairment of taste function. Impairment of taste function has been poorly evaluated in Sjögren syndrome like olfactory or (intra-nasal and oral) trigeminal disorders.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 26, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 1, 2021

Completed
1.1 years until next milestone

Study Start

First participant enrolled

July 1, 2022

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2022

Completed
Last Updated

May 25, 2022

Status Verified

May 1, 2022

Enrollment Period

Same day

First QC Date

May 26, 2021

Last Update Submit

May 24, 2022

Conditions

Keywords

Sjogren's syndromeolfactory disordertaste disorder(intra-nasal and oral) trigeminal impairments

Outcome Measures

Primary Outcomes (3)

  • Olfactory detection thresholds for Phenyl-ethyl alcohol

    Successive dilutions of odorants by a factor 2 will be realized with distilled water as solvent. The odorant stimulus will be presented in a white glass bottle filled with 4 ml of liquid. The bottle will be presented for 3 seconds, medially 1 cm under both nostrils. Odour thresholds will be assessed using an ascending staircase, binary (stimulus vs. blank) forced-choice procedure, with inter-trial intervals of 90 seconds. The two bottles will presented to the subject in random order. After sniffing each stimulus, the participant will be asked to identify the one who smelled stronger. An incorrect choice will led to increase the concentration of the stimulus in the next trial. The dilution step at which the odorant stimulus will be first detected correctly three times in a row will be recorded as the detection threshold.

    Day 0

  • Olfactory detection thresholds for Butanol

    Successive dilutions of odorants by a factor 2 will be realized with distilled water as solvent. The odorant stimulus will be presented in a white glass bottle filled with 4 ml of liquid. The bottle will be presented for 3 seconds, medially 1 cm under both nostrils. Odour thresholds will be assessed using an ascending staircase, binary (stimulus vs. blank) forced-choice procedure, with inter-trial intervals of 90 seconds. The two bottles will presented to the subject in random order. After sniffing each stimulus, the participant will be asked to identify the one who smelled stronger. An incorrect choice will led to increase the concentration of the stimulus in the next trial. The dilution step at which the odorant stimulus will be first detected correctly three times in a row will be recorded as the detection threshold.

    Day 0

  • Olfactory detection thresholds for Pyridine

    Successive dilutions of odorants by a factor 2 will be realized with distilled water as solvent. The odorant stimulus will be presented in a white glass bottle filled with 4 ml of liquid. The bottle will be presented for 3 seconds, medially 1 cm under both nostrils. Odour thresholds will be assessed using an ascending staircase, binary (stimulus vs. blank) forced-choice procedure, with inter-trial intervals of 90 seconds. The two bottles will presented to the subject in random order. After sniffing each stimulus, the participant will be asked to identify the one who smelled stronger. An incorrect choice will led to increase the concentration of the stimulus in the next trial. The dilution step at which the odorant stimulus will be first detected correctly three times in a row will be recorded as the detection threshold.

    Day 0

Secondary Outcomes (5)

  • Taste detection thresholds for salty taste

    Day 0

  • Taste detection thresholds for sweet taste

    Day 0

  • Taste detection thresholds for sour taste

    Day 0

  • Taste detection thresholds for bitter taste

    Day 0

  • Taste detection thresholds for trigeminal stimuli

    Day 0

Study Arms (2)

group 1: patients with Sjogren's syndrome

OTHER

Patients with Sjogren's syndrome

Other: Evaluation of olfactory functionOther: Evaluation of taste functionOther: Evaluation of (intra-nasal and oral) trigeminal functions

group 2: patients without sicca syndrome

OTHER

Patients without sicca syndrome

Other: Evaluation of olfactory functionOther: Evaluation of taste functionOther: Evaluation of (intra-nasal and oral) trigeminal functions

Interventions

Evaluation of olfactory function using olfactory detection thresholds

group 1: patients with Sjogren's syndromegroup 2: patients without sicca syndrome

Evaluation of taste function using taste detection thresholds

group 1: patients with Sjogren's syndromegroup 2: patients without sicca syndrome

Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.

group 1: patients with Sjogren's syndromegroup 2: patients without sicca syndrome

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • group 1 : patients with Sjogren's syndrome
  • group 2: patients without sicca syndrome
  • older than 18 years old
  • consenting to participate to the study

You may not qualify if:

  • smoking patients
  • patients with stomatitis
  • patients with upper respiratory tract infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Université de Reims Champagne-Ardenne

Reims, France

Location

MeSH Terms

Conditions

Sjogren's SyndromeTaste Disorders

Condition Hierarchy (Ancestors)

Arthritis, RheumatoidArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesXerostomiaSalivary Gland DiseasesMouth DiseasesStomatognathic DiseasesDry Eye SyndromesLacrimal Apparatus DiseasesEye DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Clovis FOGUEM, MD

    Université de Reims Champagne-Ardenne

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 26, 2021

First Posted

June 1, 2021

Study Start

July 1, 2022

Primary Completion

July 1, 2022

Study Completion

October 1, 2022

Last Updated

May 25, 2022

Record last verified: 2022-05

Locations